Evidence map›Paper›PMID 31083598›Full record

ArticleMolecules (Basel, Switzerland)2019

The Effect of Furanocoumarin Derivatives on Induction of Apoptosis and Multidrug Resistance in Human Leukemic Cells.

Tomasz Kubrak, Marcin Czop, Przemysław Kołodziej, Marta Ziaja-Sołtys, Jacek Bogucki, Anna Makuch-Kocka, David Aebisher, Janusz Kocki, Anna Bogucka-Kocka

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Tomasz KubrakDepartment of Biochemistry and General Chemistry, Faculty of Medicine, University of Rzeszow, Aleja Rejtana 16A, 35-310 Rzeszów, Poland. kubrak.tomasz@gmail.com.ORCID 0000-0002-9905-7087
Marcin CzopDepartment of Clinical Genetics, Faculty of Medicine with Dentistry Division, Medical University of Lublin, 20-059 Lublin, Poland. marcin.czop@umlub.pl.
Przemysław KołodziejChair and Department of Biology and Genetics, Faculty of Pharmacy with Medical Analytics Division, Medical University of Lublin, 20-059 Lublin, Poland. przemyslaw.kolodziej@umlub.pl.ORCID 0000-0002-3710-0860
Marta Ziaja-SołtysChair and Department of Biology and Genetics, Faculty of Pharmacy with Medical Analytics Division, Medical University of Lublin, 20-059 Lublin, Poland. marta.ziaja-soltys@umlub.pl.
Jacek BoguckiDepartment of Clinical Genetics, Faculty of Medicine with Dentistry Division, Medical University of Lublin, 20-059 Lublin, Poland. jacekbogucki@wp.pl.ORCID 0000-0002-8683-545X
Anna Makuch-KockaDepartment of Pharmacology, Faculty of Health Sciences, Medical University of Lublin, 20-059 Lublin, Poland. anna.makuch@poczta.fm.
David AebisherDepartment of Photomedicine and Physical Chemistry, Faculty of Medicine, University of Rzeszow, Aleja Rejtana 16A, 35-310 Rzeszów, Poland. daebisher@ur.edu.pl.
Janusz KockiDepartment of Clinical Genetics, Faculty of Medicine with Dentistry Division, Medical University of Lublin, 20-059 Lublin, Poland. januszkocki@umlub.pl.
Anna Bogucka-KockaChair and Department of Biology and Genetics, Faculty of Pharmacy with Medical Analytics Division, Medical University of Lublin, 20-059 Lublin, Poland. anna.kocka@tlen.pl.
Medical University of Lublin · PLUniversity of Rzeszów · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe insensitivity of cancer cells to therapeutic agents is considered to be the main cause of failure of therapy and mortality of patients with cancer. A particularly important problem in these patients is the phenomenon of multidrug resistance, consisting of abnormal, elevated expression of transport proteins (ABC family). The aim of this research included determination of IC50 values of selected furanocoumarins in the presence and absence of mitoxantrone in leukemia cells and analysis of changes in apoptosis using anexinV/IP and Casp3/IP after 24 h exposure of cell lines to selected coumarins in the presence and absence of mitoxantrone in IC50 concentrations.

methodsResearch was conducted on 3 cell lines derived from the human hematopoietic system: HL-60, HL-60/MX1 and HL-60/MX2. After exposure to coumarin compounds, cells were subjected to cytometric analysis to determine the induction of apoptosis by two methods: the Annexin V test with propidium iodide and the PhiPhiLux-G1D2 reagent containing caspase 3 antibodies.

resultsAll of the furanocoumarin derivatives studied were found to induce apoptosis in leukemia cell lines.

conclusionsOur results clearly show that the furanocoumarin derivatives are therapeutic substances with antitumor activity inducing apoptosis in human leukemia cells with phenotypes of resistance.

Indexed as

ApoptosisCell Line, TumorCell ProliferationDrug Resistance, MultipleDrug Resistance, NeoplasmFlow CytometryFurocoumarinsHL-60 CellsHumansLeukemia, Promyelocytic, AcuteFurocoumarinsapoptosisfuranocoumarinimaging flow cytometryleukemic cell linesmultidrug resistance

Identifiers

PMID31083598
PMCPMC6539621
OpenAlexW2944609375

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.